StonvexLoading…
StonvexStonvexStonvexRTW Investments purchased 11.8 million shares of Tango Therapeutics (TNGX) for approximately $164.37 million in Q1 2026, increasing its stake to roughly 3% of assets under management. The investment comes as TNGX stock has surged 840% over the past year, reflecting investor confidence in the company's lead candidate vopimetostat for MTAP-deleted cancers and its funding runway through 2028.
RTW Investments, a biotech-focused fund, purchased 11.8 million shares of Tango Therapeutics for approximately $164.37 million in Q1 2026, increasing its stake to roughly 3% of AUM. The purchase comes as TNGX stock has surged 840% over the past year. The investment reflects confidence in Tango's lead candidate vopimetostat and upcoming clinical data for MTAP-deleted cancers, with the company well-funded through 2028.
Summary and sentiment are generated by AI for educational purposes. Always verify with the original source before making investment decisions.
Risk warning
Investing in equities carries significant risk, including the potential loss of your entire investment. Volatility, liquidity, geopolitical, and currency risks can all materially affect outcomes. Past performance does not guarantee future results. Nothing on Stonvex is investment advice, a recommendation, or a solicitation to buy or sell any security. Stonvex is not a registered investment advisor (RIA), broker-dealer, or financial planner. You should consult a licensed advisor before making investment decisions and only invest capital you can afford to lose.
© 2026 Stonvex. All rights reserved.
Service not available to residents of: Belarus, China, Cuba, France, Germany, India, Iran, Japan, North Korea, Russia, South Korea, Sudan, Syria. See Terms. You must be 18 years or older to use this service.